IN VITRO ANTIBACTERIAL ACTIVITY OF CEFADROXIL CAPSULES CONSUMED BY PATIENTS IN THE HOSPITAL

Mahfudz Mahfudz; Suharjono Suharjono; Isnaeni Isnaeni; Primadi Avianto

doi:10.24071/jpsc.002162

IN VITRO ANTIBACTERIAL ACTIVITY OF CEFADROXIL CAPSULES CONSUMED BY PATIENTS IN THE HOSPITAL

Mahfudz Mahfudz, Suharjono Suharjono, Isnaeni Isnaeni, Primadi Avianto

Abstract

Clinical use of cefadroxil, particularly in Bangka Tengah Hospital, is proven beneficial to overcome mild to moderate infections which especially occur in soft tissues such as skin, upper respiratory tract, pharyngitis, tonsillitis and urinary tract. For this reason, it is necessary to procure cefadroxil to be available enough for the treatment of cases of these diseases. The cefadroxil used by the Central Bangka Hospital was obtained from several pharmaceutical industries with different prices and distributions, due to the possibility that the active raw materials and ingredients had different origins, so there was concern that the microbiological quality would be different. Drug procurement is carried out using the e-catalog or non-e catalog method. This study aimed to examine the microbiological quality of six preparations (A, B, C, D, E, and F) in terms of their inhibitory activities against Gram-positive and Gram-negative bacteria. The bioassay was carried out by diffusion agar method using Escherichia coli ATCC 29522 and Staphylococcus aureus ATCC 29523 as the bacterial test, and nutrient agar as the test medium. The inhibitory activities were compared to cefadroxil standard for measuring the ratio potency. The results showed that all samples fulfilled USP 41 requirements with potential ratio of 90% to 120% and minimum inhibitory concentration of ≤ 8 ppm and ≤ 2 ppm against Escherichia coli and Staphylococcus aureus respectively. The potency ratios to cefadroxil standard were 95.9%, 99.1%, 100.0%, 96.7%, 96.2% and 98.2% against Staphylococcus aureus while the potency ratios of 95.6%, 99.3%, 103.8%, 97.1%, 95.7% and 100.4% were achieved against Escherichia coli for A, B, C, D, E, and F samples, respectively.

Keywords

Cefadroxil; potency ratio; Escherichia coli; Staphylococcus aureus

Full Text:

PDF

References

Anonim, 1991. PeraturanPemerintah Republik Indonesia Nomor 32 Tahun 1991 Tentang Bahan Baku atau Produk Tertentu yang Dilindungi Paten Bagi Produksi Obat Di Dalam Negeri, Jakarta.

Brayfield A., 2014. Martindale: The Complete Drug Reference. 38th Edition, Pharmaceutical Press, 1, 234-247.

De Marco BA., Salgado HRN., 2018. Rapid Stability-indicative Turbidimetric Assay to Determine the Potency of Cefadroxil Monohydrate Capsules. Analytical Method. 6, 1-7.

Dinkes, 2018. Rencana Kebutuhan Obat Provinsi Kepulauan Bangka Belitung, Pangkalpinang.

Dwiaji A., Prih S., Hasbullah,Muhammad S., 2016. Evaluasi Pengadaan Obat Publik Pada JKN Berdasarkan Data e-Catalogue Tahun 2014-2015. Jurnal Ekonomi Kesehatan Indonesia, 1(1), 39-53.

Grayson ML., Cosgrove SE., Crowe S., Hope W., McCarthy JS., Mills J., Mouton JW., PatersonDL., 2018. Kucers' The Use of Antibiotics: A Clinical Review Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, 7th Edition - Three Volume Set, 370-376.

ICH, Harmonised Tripartite Guideline, 2005.Validation of analytical procedures: text and methodology-Q2 (R1), in: Proceedings of International Conference on Harmonisation, The Switzerland.

Kementerian Kesehatan RI, 1979, Farmakope Indonesia III. Jakarta. Kementerian Kesehatan Republik Indonesia.

Kementerian Kesehatan RI, 2012. Keputusan Menteri Kesehatan Republik Indonesia Nomor 094/Menkes/SK/II/2012 Tentang Harga Obat Untuk Pengadaan Pemerintah Tahun 2012. Jakarta.

Kementerian Kesehatan, 2014, Farmakope Indonesia V. Jakarta. Kementerian Kesehatan Republik Indonesia.

Kementerian Kesehatan, 2017. Formularium Nasional 2017. Jakarta. Kementerian Kesehatan Republik Indonesia

LKPP, 2018. Peraturan Lembaga Kebijakan Pengadaan Barang/Jasa Pemerintah Nomor 9 Tahun 2018 Tentang Pedoman Pelaksanaan Pengadaan Barang/Jasa Melalui Penyedia. [WWW Document]. URL www.E-katalog.lkpp.go.id

Micromedex, 2018. Cefadroxil. Micromedex–IBM Watson Health. [WWW Document] URL https://www.micromedexsolutions.com/ (accessed 3.3.18).

MIMS Indonesia, 2018. [WWW Document]. URL https://www.mims.com.indonesia

Rahim N., Naqvi SBS., Iqbal E., Bashir S., Nesar S., Khaliq UA., Hasan EK., 2013. Investigation on Pharmaceutical Quality of Different Brands of Cefadroxil Monohydrate available in Karachi, Pakistan. Indo American Journal of Pharmaceutical Research, 3(6), 4577-4583

Rahim N., Naqvi SBS., Bashir S., Rafiq K., Nesar S., 2014. Assessment of Different Brands of Cefadroxil for Their in Vitro Antibacterial Activity against Staphylococcus aureus and Escherichia coli. International Journal of Pharmaceutical Science Invention, 3(2), 1-6.

Rahim N., Naqvi SBS., Shakeel S., Iffat W and Muhammad IN., 2015. Determination of Cefadroxil in Tablet/Capsule formulations by a Validated Reverse Phase High Performance Liquid Chromatographic method. Pakistan Journal Pharmaceutical Science, 28(4), 1345-1349.

The Clinical and Laboratory Standards Institute (CLSI), 2015. M100-S25 Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement. CLSI document M100-S25. Wayne, PA: Clinical and Laboratory Standards Institute, 25th edition.

USP 41, 2018. United States Pharmacopeia. 41th edition. New York. The United States Pharmacopeial Convention.

DOI: https://doi.org/10.24071/jpsc.002162